...
首页> 外文期刊>Cerebral cortex >Inhibition of Histone Deacetylase Reinstates Hippocampus-Dependent Long-Term Synaptic Plasticity and Associative Memory in Sleep-Deprived Mice
【24h】

Inhibition of Histone Deacetylase Reinstates Hippocampus-Dependent Long-Term Synaptic Plasticity and Associative Memory in Sleep-Deprived Mice

机译:组蛋白脱乙酰酶的抑制恢复海马依赖的长期突触塑性和联合记忆在睡眠剥夺的小鼠中

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Sleep plays an important role in the establishment of long-term memory; as such, lack of sleep severely impacts domains of our health including cognitive function. Epigenetic mechanisms regulate gene transcription and protein synthesis, playing a critical role in the modulation of long-term synaptic plasticity and memory. Recent evidences indicate that transcriptional dysregulation as a result of sleep deprivation (SD) may contribute to deficits in plasticity and memory function. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA), also known as Vorinostat, a clinically approved drug for human use, has been shown to ameliorate cognitive deficits in several neurological disease models. To further explore the therapeutic effect of SAHA, we have examined its potential role in improving the SD-mediated impairments in long-term plasticity, associative plasticity, and associative memory. Here we show that SAHA preserves long-term plasticity, associative plasticity, and associative memory in SD hippocampus. Furthermore, we find that SAHA prevents SD-mediated epigenetic changes by upregulating histone acetylation, hence preserving the ERK-cAMP-responsive element-binding protein (CREB)/CREB-binding protein-brain-derived neurotrophic factor pathway in the hippocampus. These data demonstrate that modifying epigenetic mechanisms via SAHA can prevent or reverse impairments in long-term plasticity and memory that result from sleep loss. Thus, SAHA could be a potential therapeutic agent in improving SD-related memory deficits.
机译:睡眠在建立长期记忆中起着重要作用;因此,睡眠不足严重影响我们的健康领域,包括认知功能。表观遗传学机制调节基因转录和蛋白质合成,在长期突触可塑性和记忆的调节中发挥关键作用。最近的证据表明,睡眠剥夺(SD)导致的转录失调可能导致可塑性和记忆功能的缺陷。组蛋白去乙酰化酶抑制剂Suberoylanide hydroxamic acid(SAHA),也被称为伏立诺达(Vorinostat),一种临床批准的人类使用药物,已被证明可以改善几种神经疾病模型中的认知缺陷。为了进一步探索SAHA的治疗效果,我们研究了其在改善SD介导的长期可塑性、联想可塑性和联想记忆损伤方面的潜在作用。我们发现SAHA在SD海马中保留了长期可塑性、联想可塑性和联想记忆。此外,我们发现SAHA通过上调组蛋白乙酰化来阻止SD介导的表观遗传学变化,从而在海马中保留ERK-cAMP反应元件结合蛋白(CREB)/CREB结合蛋白脑源性神经营养因子途径。这些数据表明,通过SAHA修改表观遗传学机制可以预防或逆转因睡眠丧失导致的长期可塑性和记忆障碍。因此,SAHA可能成为改善SD相关记忆缺陷的潜在治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号